The authors tried to differentiate malignancy-related from nonmalignant ascites with a sequence of sensitive followed by specific ascitic-fluid parameters. There were four results of this study. First, of nine parameters investigated in a first series of 48 patients, 28 with nonmalignant and 20 with
Ascitic fluid analysis in malignancy-related ascites
β Scribed by Bruce A. Runyon; John C. Hoefs; Timothy R. Morgan
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 772 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background. Ascites in patients with hepatocellular carcinoma (HCC) is a poorly characterized subgroup of malignancy-related ascites. Not only the underlying liver disease, but also the tumor growth and spread contributes to the ascites formation. The authors differentiated ascites in HCC from other
My recent review of pharmacogenetics (1) quoted a misleading statement that a block in the metabolism of encainide would result in an absence of pharmacological effects from the drug. This statement, originally made in a paper from the United Kingdom ( 2 ) , indicated that the poor metabolizer pheno
We read with interest the recent article by Runyon on diagnosis and treatment of ascites. 1 Surprisingly, determination of cholesterol in ascitic fluid was classified as being unhelpful (table 3 of the article). The value of cholesterol in the differentiation between cirrhotic and malignant ascites